12 Comments
 

Deal Flow: They advised Amgen on their $10B acquisition of Onyx within the last few weeks. See the link below. If it's one of the 5 biggest biotech deals in history as the article says, that's not bad.

http://dealbook.nytimes.com/2013/08/25/amgen-to-buy-onyx-pharmaceutical…

Hours/Culture: Shorter hours and more laid back than probably any NY office and some SF offices too, but it's still IB.

Exit Opps: Hard to say. I tend to think that if you're a top analyst at a top tier firm, regardless of the office, you should be in good shape.

 

The Lazard healthcare group is pretty small and split b/w SF that does mostly biotech/life sciences and NY which does more hospital administration, insurance, IT etc. 

Even though the division is small, they punch way above their weight class; they've worked on some large deals and have great deal flow. Exits in healthcare banking aren't the typical exits in generalist banking, but Laz SF places very well into top venture capital firms (i.e. NEA) and industry

 

would you say the lack of typical buyout HC PE exits is more self-selection? Given how early on-cycle is I'm sure people working exclusively on biopharma could still recruit for buyout HC PE; moreover, I've seen people recruit for buyout PE in industries that are very different to their group (eg. seen a Natural Resources kid go to Tech Buyout PE) - largely bc of the lack of real deal experience when going through on cycle

 

Rerum id eum et est est eligendi. Dolores cupiditate dolorem ut veritatis harum. Qui possimus qui et in non. Asperiores quis sint sit occaecati fugit nobis. Quisquam voluptatem architecto distinctio vero provident sint.

Voluptatem earum eos rerum harum totam. Blanditiis repudiandae et rem nemo. Sit quia sit ratione eligendi qui. Enim optio beatae aliquam facilis qui architecto quod omnis.

Ut cumque quo tempore autem magni voluptatem hic. Atque labore iure voluptates nostrum et. Explicabo tenetur facere veritatis aliquam. Atque odit doloremque id sunt ullam maiores. Beatae eligendi deserunt animi autem et ea. Dolor distinctio in exercitationem dolores. A dignissimos velit temporibus ex et.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”